{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T03:46:28Z","timestamp":1793850388410,"version":"4.6.1"},"reference-count":108,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,1,19]],"date-time":"2022-01-19T00:00:00Z","timestamp":1642550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,19]],"date-time":"2022-01-19T00:00:00Z","timestamp":1642550400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"national cancer institute","doi-asserted-by":"publisher","award":["P30 CA016672"],"award-info":[{"award-number":["P30 CA016672"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The suite of marked anemia benefits that momelotinib has consistently conferred on myelofibrosis (MF) patients stem from its unique inhibitory activity on the BMP6\/ACVR1\/SMAD and IL-6\/JAK\/STAT3 pathways, resulting in decreased hepcidin (master iron regulator) expression, higher serum iron and hemoglobin levels, and restored erythropoiesis. Clinical data on momelotinib from the phase 2 and the\u00a0two\u00a0phase 3 SIMPLIFY trials consistently demonstrated high rates of sustained transfusion-independence. In a recent phase 2 translational study, 41% of the patients achieved transfusion\u00a0independence for\u2009\u2265\u200912\u00a0weeks. In the phase 3\u00a0trials\u00a0SIMPLIFY-1 and SIMPLIFY-2, 17% more JAK inhibitor-na\u00efve patients and two-fold more JAK inhibitor-treated patients achieved or maintained transfusion\u00a0independence with momelotinib versus ruxolitinib and best available therapy (89% ruxolitinib), respectively. Anemia is present in approximately a third of MF patients at diagnosis, eventually developing in nearly all patients. The need for red blood cell transfusions is an independent adverse risk factor for both overall survival and leukemic transformation. Presently, FDA-approved medications to address anemia are lacking. Momelotinib is one of the prime candidates to durably address the critical unmet needs of MF patients with moderate\/severe anemia. Importantly, momelotinib may have overall survival benefits in frontline and second-line MF patients. MOMENTUM is an international registration-track phase 3\u00a0trial further assessing momelotinib\u2019s unique constellation of anemia and other benefits in second-line MF patients; the results of the MOMENTUM trial are keenly awaited and may lead to regulatory approval of momelotinib.<\/jats:p>\n                  <jats:p>\n                    <jats:bold>Graphical abstract<\/jats:bold>\n                  <\/jats:p>","DOI":"10.1186\/s13045-021-01157-4","type":"journal-article","created":{"date-parts":[[2022,1,19]],"date-time":"2022-01-19T08:02:54Z","timestamp":1642579374000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":90,"title":["Momelotinib: an emerging treatment for myelofibrosis patients with anemia"],"prefix":"10.1186","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8044-4960","authenticated-orcid":false,"given":"Helen T.","family":"Chifotides","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4343-5712","authenticated-orcid":false,"given":"Prithviraj","family":"Bose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6912-8569","authenticated-orcid":false,"given":"Srdan","family":"Verstovsek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,19]]},"reference":[{"key":"1157_CR1","unstructured":"Bose P, Masarova L, Amin HM, Verstovsek S. Philadelphia Chromosome-Negative Myeloproliferative Neoplasms (Chapter 6) In: The MD Anderson Manual of Medical Oncology. Kantarjian HM, Wolff RA, Rieber AG, editors; 4th edition, McGraw-Hill Education; 2022, in press."},{"issue":"1","key":"1157_CR2","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1182\/blood.2019000943","volume":"136","author":"AJ Dunbar","year":"2020","unstructured":"Dunbar AJ, Rampal RK, Levine R. Leukemia secondary to myeloproliferative neoplasms. Blood. 2020;136(1):61\u201370.","journal-title":"Blood"},{"key":"1157_CR3","doi-asserted-by":"publisher","unstructured":"Pasca S, Chifotides HT, Verstovsek S, Bose P. Mutational Landscape of Blast Phase Myeloproliferative Neoplasms (MPN-BP) and Antecedent MPN. Chapter 4 In: Bartalucci N, editor. Cellular and Molecular Aspects of Myeloproliferative Neoplasms \u2500 Part B, Vol. 366, 1st edition, In the Book Series: International Review of Cell and Molecular Biology, Bartalucci N, Galluzzi L, editors. Academic Press, 2022; pp. 83\u2013124. https:\/\/doi.org\/10.1016\/bs.ircmb.2021.02.008.","DOI":"10.1016\/bs.ircmb.2021.02.008"},{"key":"1157_CR4","first-page":"89","volume":"7","author":"TI Mughal","year":"2014","unstructured":"Mughal TI, Vaddi K, Sarlis NJ, Verstovsek S. Myelofibrosis-associated complications: pathogenesis, clinical manifestations, and effects on outcomes. Int J Gen Med. 2014;7:89\u2013101.","journal-title":"Int J Gen Med"},{"issue":"2","key":"1157_CR5","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/nrd3264","volume":"10","author":"A Quint\u00e1s-Cardama","year":"2011","unstructured":"Quint\u00e1s-Cardama A, Kantarjian H, Cortes J, Verstovsek S. Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond. Nat Rev Drug Discov. 2011;10(2):127\u201340.","journal-title":"Nat Rev Drug Discov"},{"issue":"6","key":"1157_CR6","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1182\/blood-2016-10-695940","volume":"129","author":"W Vainchenker","year":"2017","unstructured":"Vainchenker W, Kralovics R. Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms. Blood. 2017;129(6):667\u201379. https:\/\/doi.org\/10.1182\/blood-2016-10-695940.","journal-title":"Blood"},{"issue":"4","key":"1157_CR7","doi-asserted-by":"crossref","first-page":"e424","DOI":"10.1097\/HS9.0000000000000424","volume":"4","author":"P Bose","year":"2020","unstructured":"Bose P, Verstovsek S. JAK inhibition for the treatment of myelofibrosis: limitations and future perspectives. HemaSphere. 2020;4(4):e424.","journal-title":"HemaSphere"},{"key":"1157_CR8","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s40265-015-0351-8","volume":"75","author":"GL Plosker","year":"2015","unstructured":"Plosker GL. Ruxolitinib: a review of its use in patients with myelofibrosis. Drugs. 2015;75:297\u2013308.","journal-title":"Drugs"},{"issue":"1","key":"1157_CR9","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s13045-017-0527-7","volume":"10","author":"S Verstovsek","year":"2017","unstructured":"Verstovsek S, Gotlib J, Mesa RA, et al. Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses. J Hematol Oncol. 2017;10(1):156.","journal-title":"J Hematol Oncol"},{"key":"1157_CR10","doi-asserted-by":"publisher","unstructured":"Verstovsek S, Parasuraman S, Yu J, et al. Real-world survival of US patients with intermediate- to high-risk myelofibrosis: impact of ruxolitinib approval. Ann Hematol. 2022;101:131\u2013137. https:\/\/doi.org\/10.1007\/s00277-021-04682-x.","DOI":"10.1007\/s00277-021-04682-x"},{"key":"1157_CR11","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1007\/s12185-019-02758-z","volume":"111","author":"P Bose","year":"2020","unstructured":"Bose P, Verstovsek S. Mutational profiling in myelofibrosis; implications for management. Int J Hematol. 2020;111:192\u20139.","journal-title":"Int J Hematol"},{"issue":"10","key":"1157_CR12","doi-asserted-by":"publisher","first-page":"2891","DOI":"10.3390\/cancers12102891","volume":"12","author":"P Bose","year":"2020","unstructured":"Bose P, Masarova L, Verstovsek S. Novel concepts of treatment for patients with myelofibrosis and related neoplasms. Cancers (Basel). 2020;12(10):2891. https:\/\/doi.org\/10.3390\/cancers12102891.","journal-title":"Cancers (Basel)"},{"issue":"8","key":"1157_CR13","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1080\/10428194.2020.1749606","volume":"61","author":"P Bose","year":"2020","unstructured":"Bose P, Verstovsek S. Management of myelofibrosis after ruxolitinib failure. Leuk Lymphoma. 2020;61(8):1797\u20131809.","journal-title":"Leuk Lymphoma"},{"issue":"10","key":"1157_CR14","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1080\/21678707.2019.1664900","volume":"7","author":"P Bose","year":"2019","unstructured":"Bose P. Advances in potential treatment options for myeloproliferative neoplasm associated myelofibrosis. Expert Opin Orphan Drugs. 2019;7(10):415\u201325.","journal-title":"Expert Opin Orphan Drugs"},{"issue":"2","key":"1157_CR15","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1182\/blood-2017-04-742288","volume":"130","author":"P Bose","year":"2017","unstructured":"Bose P, Verstovsek S. JAK2 inhibitors for myeloproliferative neoplasms: What is next? Blood. 2017;130(2):115\u201325.","journal-title":"Blood"},{"key":"1157_CR16","doi-asserted-by":"crossref","first-page":"100715","DOI":"10.1016\/j.blre.2020.100715","volume":"42","author":"S Asher","year":"2020","unstructured":"Asher S, McLornan DP, Harrison CN. Current and future therapies for myelofibrosis. Blood Rev. 2020;42:100715.","journal-title":"Blood Rev"},{"issue":"1","key":"1157_CR17","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1097\/HS9.0000000000000001","volume":"1","author":"L Naymagon","year":"2017","unstructured":"Naymagon L, Mascarenhas J. Myelofibrosis-related anemia: current and emerging therapeutic strategies. HemaSphere. 2017;1(1):e1.","journal-title":"HemaSphere"},{"key":"1157_CR18","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1182\/blood-2008-07-170449","volume":"113","author":"F Cervantes","year":"2009","unstructured":"Cervantes F, Dupriez B, Pereira A, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood. 2009;113:2895\u2013901.","journal-title":"Blood"},{"key":"1157_CR19","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1007\/s11899-018-0447-9","volume":"13","author":"P Bose","year":"2018","unstructured":"Bose P, Verstovsek S. Management of myelofibrosis-related cytopenias. Curr Hematol Malign Rep. 2018;13:164\u201372. https:\/\/doi.org\/10.1007\/s11899-018-0447-9.","journal-title":"Curr Hematol Malign Rep"},{"key":"1157_CR20","doi-asserted-by":"crossref","first-page":"100716","DOI":"10.1016\/j.blre.2020.100716","volume":"42","author":"RM Scherber","year":"2020","unstructured":"Scherber RM, Mesa RA. Management of challenging myelofibrosis after JAK inhibitor failure and\/or progression. Blood Rev. 2020;42:100716.","journal-title":"Blood Rev"},{"issue":"9","key":"1157_CR21","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2009-09-245837","volume":"115","author":"F Passamonti","year":"2010","unstructured":"Passamonti F, Cervantes F, Vannucchi AM, et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood. 2010;115(9):1703\u20138.","journal-title":"Blood"},{"key":"1157_CR22","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.mayocp.2011.11.001","volume":"87","author":"A Tefferi","year":"2012","unstructured":"Tefferi A, Lasho TL, Jimma T, et al. One thousand patients with primary myelofibrosis: the Mayo Clinic experience. Mayo Clin Proc. 2012;87:25\u201333.","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"1157_CR23","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3324\/haematol.2010.031831","volume":"96","author":"C Elena","year":"2011","unstructured":"Elena C, Passamonti F, Rumi E, et al. Red blood cell transfusion-dependency implies a poor survival in myelofibrosis irrespective of IPSS and DIPSS. Haematologica. 2011;96(1):167\u201370.","journal-title":"Haematologica"},{"key":"1157_CR24","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1038\/s41375-018-0028-x","volume":"32","author":"M Nicolosi","year":"2018","unstructured":"Nicolosi M, Mudireddy M, Lasho TL, et al. Sex and degree of severity influence the prognostic impact of anemia in primary myelofibrosis: analysis based on 1109 consecutive patients. Leukemia. 2018;32:1254\u20138.","journal-title":"Leukemia"},{"issue":"11","key":"1157_CR25","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1002\/ajh.24881","volume":"92","author":"A Tefferi","year":"2017","unstructured":"Tefferi A, Mudireddy M, Ganget N, et al. Risk factors and a prognostic model for post-splenectomy survival in myelofibrosis. Am J Hematol. 2017;92(11):1187\u201392.","journal-title":"Am J Hematol"},{"issue":"4","key":"1157_CR26","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1200\/JCO.2010.32.2446","volume":"29","author":"N Gangat","year":"2011","unstructured":"Gangat N, Caramazza D, Vaidya R, et al. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol. 2011;29(4):392\u20137.","journal-title":"J Clin Oncol"},{"issue":"7","key":"1157_CR27","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1182\/blood-2014-05-578435","volume":"124","author":"E Rumi","year":"2014","unstructured":"Rumi E, Pietra D, Pascutto C, et al. Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis. Blood. 2014;124(7):1062\u20139.","journal-title":"Blood"},{"issue":"4","key":"1157_CR28","doi-asserted-by":"crossref","first-page":"e415","DOI":"10.1038\/bcj.2016.22","volume":"6","author":"D Barraco","year":"2016","unstructured":"Barraco D, Elala YC, Lasho TL, et al. Molecular correlates of anemia in primary myelofibrosis: a significant and independent association with U2AF1 mutations. Blood Cancer J. 2016;6(4):e415.","journal-title":"Blood Cancer J"},{"issue":"9","key":"1157_CR29","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","volume":"366","author":"S Verstovsek","year":"2012","unstructured":"Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012;366(9):799\u2013807.","journal-title":"N Engl J Med"},{"issue":"9","key":"1157_CR30","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJMoa1110556","volume":"366","author":"C Harrison","year":"2012","unstructured":"Harrison C, Kiladjian J-J, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012;366(9):787\u201398.","journal-title":"N Engl J Med"},{"issue":"4","key":"1157_CR31","doi-asserted-by":"crossref","first-page":"479","DOI":"10.3324\/haematol.2014.115840","volume":"100","author":"S Verstovsek","year":"2015","unstructured":"Verstovsek S, Mesa RA, Gotlib J, et al. Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I. Haematologica. 2015;100(4):479\u201388.","journal-title":"Haematologica"},{"key":"1157_CR32","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1038\/leu.2016.148","volume":"30","author":"CN Harrison","year":"2016","unstructured":"Harrison CN, Vannucchi AM, Kiladjian J-J, et al. Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis. Leukemia. 2016;30:1701\u20137.","journal-title":"Leukemia"},{"issue":"23","key":"1157_CR33","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1182\/blood.V126.23.1604.1604","volume":"126","author":"V Gupta","year":"2015","unstructured":"Gupta V, Harrison C, Hexner EO, et al. The impact of anemia on overall survival in patients with myelofibrosis treated with ruxolitinib: an exploratory analysis of the COMFORT studies. Blood. 2015;126(23):1604. https:\/\/doi.org\/10.1182\/blood.V126.23.1604.1604.","journal-title":"Blood"},{"issue":"12","key":"1157_CR34","doi-asserted-by":"crossref","first-page":"e482","DOI":"10.3324\/haematol.2016.151449","volume":"101","author":"V Gupta","year":"2016","unstructured":"Gupta V, Harrison C, Hexner EO, et al. The impact of anemia on overall survival in patients with myelofibrosis treated with ruxolitinib in the COMFORT studies. Haematologica. 2016;101(12):e482\u20134.","journal-title":"Haematologica"},{"issue":"10","key":"1157_CR35","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.3109\/10428194.2016.1146950","volume":"57","author":"HK Al-Ali","year":"2016","unstructured":"Al-Ali HK, Stalbovskaya V, Gopalakrishna P, et al. Impact of ruxolitinib treatment on the hemoglobin dynamics and the negative prognosis of anemia in patients with myelofibrosis. Leuk Lymphoma. 2016;57(10):2464\u20137.","journal-title":"Leuk Lymphoma"},{"key":"1157_CR36","doi-asserted-by":"publisher","unstructured":"Cervantes F, Ross DM, Radinoff A, et al. Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis (MF) and anemia: the REALISE phase 2 study. Leukemia. 2021;35:3455\u20133465. https:\/\/doi.org\/10.1038\/s41375-021-01261-x.","DOI":"10.1038\/s41375-021-01261-x"},{"key":"1157_CR37","doi-asserted-by":"publisher","unstructured":"Bose P, Verstovsek S. SOHO State of the Art Updates and Next Questions: identifying and treating \u201cprogression\u201d in myelofibrosis. Clin Lymphoma Myeloma Leuk. 2021;21(10):641\u201349. https:\/\/doi.org\/10.1016\/j.clml.2021.10.002.","DOI":"10.1016\/j.clml.2021.10.002"},{"key":"1157_CR38","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1007\/s00277-020-04002-9","volume":"99","author":"CN Harrison","year":"2020","unstructured":"Harrison CN, Schaap N, Mesa RA. Management of myelofibrosis after ruxolitinib failure. Ann Hematol. 2020;99:1177\u201391.","journal-title":"Ann Hematol"},{"key":"1157_CR39","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s00277-017-3194-4","volume":"97","author":"AT Kuykendall","year":"2018","unstructured":"Kuykendall AT, Shah S, Talati C, et al. Between a rux and a hard place: evaluating salvage treatment and outcomes in myelofibrosis after ruxolitinib discontinuation. Ann Hematol. 2018;97:435\u201341.","journal-title":"Ann Hematol"},{"key":"1157_CR40","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s00277-016-2884-7","volume":"96","author":"M Breccia","year":"2017","unstructured":"Breccia M, Andriani A, Montanaro M, et al. Ruxolitinib in clinical practice for primary and secondary myelofibrosis: an analysis of safety and efficacy of Gruppo Laziale of Ph-negative MPN. Ann Hematol. 2017;96:387\u201391.","journal-title":"Ann Hematol"},{"key":"1157_CR41","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/s41408-020-00392-1","volume":"11","author":"F Palandri","year":"2021","unstructured":"Palandri F, Palumbo GA, Bonifacio M, et al. Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis. Blood Cancer J. 2021;11:4.","journal-title":"Blood Cancer J"},{"key":"1157_CR42","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1182\/blood-2017-05-783225","volume":"130","author":"KJ Newberry","year":"2017","unstructured":"Newberry KJ, Patel K, Masarova L, et al. Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation. Blood. 2017;130:1125\u201331.","journal-title":"Blood"},{"key":"1157_CR43","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1002\/cncr.32664","volume":"126","author":"F Palandri","year":"2020","unstructured":"Palandri F, Breccia M, Bonifacio M, et al. Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis. Cancer. 2020;126:1243\u201352.","journal-title":"Cancer"},{"issue":"15","key":"1157_CR44","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1002\/cncr.33541","volume":"127","author":"F Palandri","year":"2021","unstructured":"Palandri F, Tribelli M, Breccia M, et al. Ruxolitinib rechallenge in resistant or intolerant patients with myelofibrosis: frequency, therapeutic effects, and impact on outcome. Cancer. 2021;127(15):2657\u201365.","journal-title":"Cancer"},{"issue":"7","key":"1157_CR45","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1080\/13696998.2020.1741381","volume":"23","author":"J Mascarenhas","year":"2020","unstructured":"Mascarenhas J, Mehra M, He J, Potluri R, Loefgren C. Patient characteristics and outcomes after ruxolitinib discontinuation in patients with myelofibrosis. J Med Econ. 2020;23(7):721\u201337.","journal-title":"J Med Econ"},{"key":"1157_CR46","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1001\/jamaoncol.2015.1590","volume":"1","author":"A Pardanani","year":"2015","unstructured":"Pardanani A, Harrison C, Cortes JE, et al. Safety and efficacy of fedratinib in patients with primary or secondary myelofibrosis: a randomized clinical trial. JAMA Oncol. 2015;1:643\u201351.","journal-title":"JAMA Oncol"},{"key":"1157_CR47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41375-020-0954-2","volume":"35","author":"M Talpaz","year":"2021","unstructured":"Talpaz M, Kiladjian J-J. Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis. Leukemia. 2021;35:1\u201317.","journal-title":"Leukemia"},{"issue":"8","key":"1157_CR48","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1182\/bloodadvances.2019000954","volume":"4","author":"A Mullally","year":"2020","unstructured":"Mullally A, Hood J, Harrison C, Mesa R. Fedratinib in myelofibrosis. Blood Adv. 2020;4(8):1792\u2013800.","journal-title":"Blood Adv"},{"key":"1157_CR49","doi-asserted-by":"crossref","first-page":"e317","DOI":"10.1016\/S2352-3026(17)30088-1","volume":"4","author":"CN Harrison","year":"2017","unstructured":"Harrison CN, Schaap N, Vannucchi AM, et al. Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study. Lancet Haematol. 2017;4:e317\u201324.","journal-title":"Lancet Haematol"},{"issue":"6","key":"1157_CR50","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1002\/ajh.25777","volume":"95","author":"CN Harrison","year":"2020","unstructured":"Harrison CN, Schaap N, Vannucchi AM, et al. Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: an updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure. Am J Hematol. 2020;95(6):594\u2013603.","journal-title":"Am J Hematol"},{"key":"1157_CR51","doi-asserted-by":"crossref","first-page":"e225","DOI":"10.1016\/S2352-3026(17)30027-3","volume":"4","author":"RA Mesa","year":"2017","unstructured":"Mesa RA, Vannucchi AM, Mead A, et al. Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial. Lancet Haematol. 2017;4:e225\u201336.","journal-title":"Lancet Haematol"},{"key":"1157_CR52","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1001\/jamaoncol.2017.5818","volume":"4","author":"J Mascarenhas","year":"2018","unstructured":"Mascarenhas J, Hoffman R, Talpaz M, et al. Pacritinib vs best available therapy, including ruxolitinib, in patients with myelofibrosis: a randomized clinical trial. JAMA Oncol. 2018;4:652\u20139.","journal-title":"JAMA Oncol"},{"issue":"7","key":"1157_CR53","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.clml.2020.01.008","volume":"20","author":"BK Marcellino","year":"2020","unstructured":"Marcellino BK, Verstovsek S, Mascarenhas J. The myelodepletive phenotype in myelofibrosis: clinical relevance and therapeutic implications. Clin Lymphoma Myeloma Leuk. 2020;20(7):415\u201321.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"23","key":"1157_CR54","first-page":"5929","volume":"4","author":"D Tremblay","year":"2020","unstructured":"Tremblay D, Mesa R, Scott B, et al. Pacritinib demonstrates spleen volume reduction in patients with myelofibrosis independent of JAK2V617F allele burden. Blood Adv. 2020;4(23):5929\u201335.","journal-title":"Blood Adv"},{"issue":"9","key":"1157_CR55","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1182\/bloodadvances.2019001084","volume":"4","author":"K Gowin","year":"2020","unstructured":"Gowin K, Ballen K, Ahn KW, et al. Survival following allogeneic transplant in patients with myelofibrosis. Blood Adv. 2020;4(9):1965\u201373.","journal-title":"Blood Adv"},{"issue":"20","key":"1157_CR56","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1182\/blood-2018-12-890889","volume":"133","author":"N Gagelmann","year":"2019","unstructured":"Gagelmann N, Ditschkowski M, Bogdanov R, et al. Comprehensive clinical-molecular transplant scoring system for myelofibrosis undergoing stem cell transplantation. Blood. 2019;133(20):2233\u201342.","journal-title":"Blood"},{"issue":"3","key":"1157_CR57","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.bbmt.2015.10.005","volume":"22","author":"M Shanavas","year":"2016","unstructured":"Shanavas M, Popat U, Michaelis LC, et al. Outcomes of allogeneic hematopoietic cell transplantation in patients with myelofibrosis with prior exposure to JAK1\/2 inhibitors. Biol Blood Marrow Transplant. 2016;22(3):432\u201340.","journal-title":"Biol Blood Marrow Transplant"},{"key":"1157_CR58","doi-asserted-by":"publisher","unstructured":"Kr\u00f6ger N, Sbianchi G, Sirait T, et al. Impact of prior JAK-inhibitor therapy with ruxolitinib on outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis: a study of the CMWP of EBMT. Leukemia. 2021;35:3551\u20133560. https:\/\/doi.org\/10.1038\/s41375-021-01276-4.","DOI":"10.1038\/s41375-021-01276-4"},{"issue":"8","key":"1157_CR59","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.3390\/cancers12082278","volume":"12","author":"AT Kuykendall","year":"2020","unstructured":"Kuykendall AT, Horvat NP, Pandey G, et al. Finding a Jill for JAK: assessing past, present, and future JAK inhibitor combination approaches in myelofibrosis. Cancers. 2020;12(8):2278.","journal-title":"Cancers"},{"issue":"7","key":"1157_CR60","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1182\/blood-2002-09-2928","volume":"101","author":"RA Mesa","year":"2003","unstructured":"Mesa RA, Pardanani A, Li C-Y, et al. A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia. Blood. 2003;101(7):2534\u201341.","journal-title":"Blood"},{"issue":"3","key":"1157_CR61","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1200\/JCO.2004.08.160","volume":"22","author":"M Marchetti","year":"2004","unstructured":"Marchetti M, Barosi G, Balestri F, et al. Low-dose thalidomide ameliorates cytopenias and splenomegaly in myelofibrosis with myeloid metaplasia: a phase II trial. J Clin Oncol. 2004;22(3):424\u201331.","journal-title":"J Clin Oncol"},{"issue":"7","key":"1157_CR62","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.3324\/haematol.12416","volume":"93","author":"R Weinkove","year":"2008","unstructured":"Weinkove R, Reilly JT, McMullin MF, et al. Low-dose thalidomide in myelofibrosis. Haematologica. 2008;93(7):1100\u20131.","journal-title":"Haematologica"},{"issue":"Suppl. 1","key":"1157_CR63","doi-asserted-by":"publisher","first-page":"4163","DOI":"10.1182\/blood-2019-127661","volume":"134","author":"RK Rampal","year":"2019","unstructured":"Rampal RK, Verstovsek S, Devlin SM, et al. Safety and efficacy of combined ruxolitinib and thalidomide in patients with myelofibrosis: a phase II study. Blood. 2019;134(Suppl. 1):4163. https:\/\/doi.org\/10.1182\/blood-2019-127661.","journal-title":"Blood"},{"issue":"23","key":"1157_CR64","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1182\/blood.V126.23.1618.1618","volume":"126","author":"KL Gowin","year":"2015","unstructured":"Gowin KL, Kosiorek HE, Dueck AC, et al. Final analysis of a multicenter pilot phase 2 study of ruxolitinib and danazol in patients with myelofibrosis. Blood. 2015;126(23):1618. https:\/\/doi.org\/10.1182\/blood.V126.23.1618.1618.","journal-title":"Blood"},{"issue":"1","key":"1157_CR65","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1182\/asheducation-2017.1.489","volume":"2017","author":"CN Harrison","year":"2017","unstructured":"Harrison CN, McLornan DP. Current treatment algorithm for the management of patients with myelofibrosis, JAK inhibitors, and beyond. Hematol Am Soc Hematol Educ Program. 2017;2017(1):489\u201397. https:\/\/doi.org\/10.1182\/asheducation-2017.1.489.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"13","key":"1157_CR66","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1182\/blood-2016-09-740092","volume":"129","author":"M Asshoff","year":"2017","unstructured":"Asshoff M, Petzer V, Warr MR, et al. Momelotinib inhibits ACVR1\/ALK2, decreases hepcidin production, and ameliorates anemia of chronic disease in rodents. Blood. 2017;129(13):1823\u201330.","journal-title":"Blood"},{"issue":"18","key":"1157_CR67","doi-asserted-by":"crossref","first-page":"4282","DOI":"10.1182\/bloodadvances.2020002662","volume":"4","author":"ST Oh","year":"2020","unstructured":"Oh ST, Talpaz M, Gerds AT, et al. ACVR1\/JAK1\/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trial. Blood Adv. 2020;4(18):4282\u201391.","journal-title":"Blood Adv"},{"key":"1157_CR68","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1177\/1535370219828694","volume":"244","author":"DH Wu","year":"2019","unstructured":"Wu DH, Hatzopoulos AK. Bone morphogenetic protein signaling in inflammation. Expert Biol Med. 2019;244:147\u201356. https:\/\/doi.org\/10.1177\/1535370219828694","journal-title":"Expert Biol Med"},{"issue":"12","key":"1157_CR69","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1056\/NEJMra1804281","volume":"381","author":"T Ganz","year":"2019","unstructured":"Ganz T. Anemia of inflammation. N Engl J Med. 2019;381(12):1148\u201357.","journal-title":"N Engl J Med"},{"key":"1157_CR70","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1152\/physrev.00008.2013","volume":"93","author":"T Ganz","year":"2013","unstructured":"Ganz T. Systemic iron homeostasis. Physiol Rev. 2013;93:1721\u201341.","journal-title":"Physiol Rev"},{"issue":"4","key":"1157_CR71","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/ng.335","volume":"41","author":"B Andriopoulos","year":"2009","unstructured":"Andriopoulos B, Corradini E, Xia Y, et al. BMP6 is a key endogenous regulator of hepcidin expression and iron metabolism. Nat Genet. 2009;41(4):482\u20137.","journal-title":"Nat Genet"},{"key":"1157_CR72","doi-asserted-by":"crossref","first-page":"85","DOI":"10.3390\/medicines6030085","volume":"6","author":"A Yiannikourides","year":"2019","unstructured":"Yiannikourides A, Latunde-Dada GO. A short review of iron metabolism and pathophysiology of iron disorders. Medicines (Basel). 2019;6:85.","journal-title":"Medicines"},{"key":"1157_CR73","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/bs.vh.2019.01.004","volume":"110","author":"L Silvestri","year":"2019","unstructured":"Silvestri L, Nai A, Dulja A, Pagani A. Hepcidin and the BMP-SMAD pathway: an unexpected liaison. Vitam Horm. 2019;110:71\u201399.","journal-title":"Vitam Horm"},{"key":"1157_CR74","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/bs.vh.2019.01.002","volume":"110","author":"YZ Ginzburg","year":"2019","unstructured":"Ginzburg YZ. Hepcidin-ferroportin axis in health and disease. Vitam Horm. 2019;110:17\u201345.","journal-title":"Vitam Horm"},{"key":"1157_CR75","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/bs.vh.2019.01.005","volume":"110","author":"MP Roth","year":"2019","unstructured":"Roth MP, Meynard D, Coppin H. Regulators of hepcidin expression. Vitam Horm. 2019;110:101\u201329.","journal-title":"Vitam Horm"},{"issue":"2","key":"1157_CR76","doi-asserted-by":"crossref","first-page":"260","DOI":"10.3324\/haematol.2019.232124","volume":"105","author":"C Camaschella","year":"2020","unstructured":"Camaschella C, Nai A, Silvestri L. Iron metabolism and iron disorders revisited in the hepcidin era. Haematologica. 2020;105(2):260\u201372.","journal-title":"Haematologica"},{"key":"1157_CR77","doi-asserted-by":"publisher","first-page":"127","DOI":"10.3390\/ph11040127","volume":"11","author":"A Katsarou","year":"2015","unstructured":"Katsarou A, Pantopoulos K. Hepcidin therapeutics. Pharmaceuticals. 2015;11:127. https:\/\/doi.org\/10.3390\/ph11040127.","journal-title":"Pharmaceuticals"},{"issue":"5","key":"1157_CR78","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1002\/hep4.1717","volume":"5","author":"KV Kowdley","year":"2021","unstructured":"Kowdley KV, Gochanour EM, Sundaram V, Shah RA, Handa P. Hepcidin signaling in health and disease: ironing out the details. Hepatol Commun. 2021;5(5):723\u201335.","journal-title":"Hepatol Commun"},{"issue":"9","key":"1157_CR79","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1172\/JCI200420945","volume":"113","author":"E Nemeth","year":"2004","unstructured":"Nemeth E, Rivera S, Gabayan V, et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Investig. 2004;113(9):1271\u20136.","journal-title":"J Clin Investig"},{"issue":"9","key":"1157_CR80","doi-asserted-by":"crossref","first-page":"3204","DOI":"10.1182\/blood-2006-06-027631","volume":"108","author":"DM Wrighting","year":"2006","unstructured":"Wrighting DM, Andrews NC. Interleukin-6 induces hepcidin expression through STAT3. Blood. 2006;108(9):3204\u20139.","journal-title":"Blood"},{"key":"1157_CR81","doi-asserted-by":"crossref","first-page":"170","DOI":"10.3390\/ph12040170","volume":"12","author":"ZJ Hawula","year":"2019","unstructured":"Hawula ZJ, Wallace DF, Subramaniam VN, Rishi G. Therapeutic advances in regulating the hepcidin\/ferroportin axis. Pharmaceuticals. 2019;12:170.","journal-title":"Pharmaceuticals"},{"issue":"14","key":"1157_CR82","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1182\/blood-2018-06-857995","volume":"132","author":"J Arezes","year":"2018","unstructured":"Arezes J, Foy N, McHugh K, et al. Erythroferrone inhibits the induction of hepcidin by BMP6. Blood. 2018;132(14):1473\u20137.","journal-title":"Blood"},{"key":"1157_CR83","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1002\/ajh.23406","volume":"88","author":"A Pardanani","year":"2013","unstructured":"Pardanani A, Finke C, Adbdelrahman RA, et al. Associations and prognostic interactions between circulating levels of hepcidin, ferritin and inflammatory cytokines in primary myelofibrosis. Am J Hematol. 2013;88:312\u20136.","journal-title":"Am J Hematol"},{"issue":"Suppl. 1","key":"1157_CR84","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1182\/blood-2018-99-113661","volume":"132","author":"A Zhou","year":"2018","unstructured":"Zhou A, Allen MJ, Fulbright M, et al. Hepcidin is elevated in primary and secondary myelofibrosis and correlates with IL-6 and IL-2R\u03b1 but is high in patients treated with ruxolitinib. Blood. 2018;132(Suppl. 1):1760. https:\/\/doi.org\/10.1182\/blood-2018-99-113661.","journal-title":"Blood"},{"issue":"12","key":"1157_CR85","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJMoa1002028","volume":"363","author":"S Verstovsek","year":"2010","unstructured":"Verstovsek S, Kantarjian H, Mesa RA, et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med. 2010;363(12):1117\u201327.","journal-title":"N Engl J Med"},{"issue":"4","key":"1157_CR86","doi-asserted-by":"crossref","first-page":"951","DOI":"10.2353\/ajpath.2008.071030","volume":"172","author":"O Bock","year":"2008","unstructured":"Bock O, Hoftmann J, Theophile K, et al. Bone morphogenetic proteins are overexpressed in the bone marrow of primary myelofibrosis and are apparently induced by fibrogenic cytokines. Am J Pathol. 2008;172(4):951\u201360.","journal-title":"Am J Pathol"},{"issue":"7","key":"1157_CR87","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1369\/jhc.6A7164.2007","volume":"55","author":"R Garimella","year":"2007","unstructured":"Garimella R, Kacena MA, Tague SE, et al. Expression of bone morphogenetic proteins and their receptors in the bone marrow of megakaryocytes of GATA-1low mice: a possible role in osteosclerosis. J Histochem Cytochem. 2007;55(7):745\u201352.","journal-title":"J Histochem Cytochem"},{"issue":"8","key":"1157_CR88","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1016\/j.ajpath.2017.04.006","volume":"187","author":"GB Erba","year":"2017","unstructured":"Erba GB, Gruppi C, Corada M, et al. Endothelial-to-mesenchymal transition in bone marrow and spleen of primary myelofibrosis. Am J Pathol. 2017;187(8):1879\u2013992.","journal-title":"Am J Pathol"},{"issue":"1","key":"1157_CR89","doi-asserted-by":"crossref","first-page":"94","DOI":"10.3324\/haematol.2016.148924","volume":"102","author":"V Gupta","year":"2017","unstructured":"Gupta V, Mesa RA, Deininger MWN, et al. A phase 1\/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosis. Haematologica. 2017;102(1):94\u2013102.","journal-title":"Haematologica"},{"issue":"12","key":"1157_CR90","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.2217\/fon-2020-1048","volume":"17","author":"S Verstovsek","year":"2021","unstructured":"Verstovsek S, Chen C-C, Egyed M, et al. MOMENTUM: Momelotinib vs. danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic. Future Oncol. 2021;17(12):1449\u201358.","journal-title":"Future Oncol"},{"issue":"Suppl. 1","key":"1157_CR91","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1182\/blood-2020-135872","volume":"136","author":"S Verstovsek","year":"2020","unstructured":"Verstovsek S, Egyed M, Lech-Maranda E, et al. Robust overall survival and sustained efficacy outcomes during long term exposure to momelotinib in JAK inhibitor na\u00efve and previously JAK inhibitor treated intermediate\/high risk myelofibrosis patients. Blood. 2020;136(Suppl. 1):51\u20132. https:\/\/doi.org\/10.1182\/blood-2020-135872.","journal-title":"Blood"},{"key":"1157_CR92","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1038\/leu.2013.71","volume":"27","author":"A Pardanani","year":"2013","unstructured":"Pardanani A, Laborde RR, Lasho TL, et al. Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis. Leukemia. 2013;27:1322\u20137.","journal-title":"Leukemia"},{"key":"1157_CR93","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1038\/leu.2017.330","volume":"32","author":"A Pardanani","year":"2018","unstructured":"Pardanani A, Gotlib J, Roberts AW, et al. Long-term efficacy and safety of momelotinib, a JAK1 and JAK2 inhibitor, for the treatment of myelofibrosis. Leukemia. 2018;32:1034\u201351. https:\/\/doi.org\/10.1038\/leu.2017.330.","journal-title":"Leukemia"},{"key":"1157_CR94","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/s41408-018-0067-6","volume":"8","author":"A Tefferi","year":"2018","unstructured":"Tefferi A, Barraco D, Lasho TL, et al. Momelotinib therapy for myelofibrosis: a 7-year follow-up. Blood Cancer J. 2018;8:29.","journal-title":"Blood Cancer J"},{"issue":"34","key":"1157_CR95","doi-asserted-by":"crossref","first-page":"3844","DOI":"10.1200\/JCO.2017.73.4418","volume":"35","author":"RA Mesa","year":"2017","unstructured":"Mesa RA, Kiladjian J-J, Catalano JV, et al. SIMPLIFY-1: a phase III randomized trial of momelotinib versus ruxolitinib in Janus kinase inhibitor-na\u00efve patients with myelofibrosis. J Clin Oncol. 2017;35(34):3844\u201350.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1157_CR96","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1016\/S2352-3026(17)30237-5","volume":"5","author":"CN Harrison","year":"2018","unstructured":"Harrison CN, Vannucchi AM, Platzbecker U, et al. Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial. Lancet Haematol. 2018;5(2):e73\u201381.","journal-title":"Lancet Haematol"},{"key":"1157_CR97","doi-asserted-by":"publisher","unstructured":"Kiladjian J-J, Platzbecker U, Mayer J, et al. Improved transfusion independence rates for momelotinib vs ruxolitinib in anemic JAKi-na\u00efve myelofibrosis patients independent of baseline platelet or transfusion status. HemaSphere. 2021;5(S2):EP1081. https:\/\/doi.org\/10.1097\/HS9.0000000000000566.","DOI":"10.1097\/HS9.0000000000000566"},{"issue":"Suppl. 1","key":"1157_CR98","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1182\/blood-2019-122506","volume":"134","author":"RA Mesa","year":"2019","unstructured":"Mesa RA, Catalano J, Cervantes F, et al. Dynamic and time-to-event analyses demonstrate marked reduction in transfusion requirements for Janus kinase inhibitor-na\u00efve myelofibrosis patients treated with momelotinib compared head-to-head with ruxolitinib. Blood. 2019;134(Suppl. 1):1663.","journal-title":"Blood"},{"key":"1157_CR99","doi-asserted-by":"publisher","unstructured":"Gupta V, Egyed M, Kirgner I, et al. Momelotinib dose-intensity is maintained in JAK-inhibitor na\u00efve and previously JAK inhibitor treated intermediate\/high-risk myelofibrosis patients. HemaSphere. 2020;4(S1):EP1103. https:\/\/doi.org\/10.1097\/HS9.0000000000000404.","DOI":"10.1097\/HS9.0000000000000404"},{"key":"1157_CR100","doi-asserted-by":"publisher","first-page":"13","DOI":"10.2147\/OTT.S53348","volume":"7","author":"S Verstovsek","year":"2014","unstructured":"Verstovsek S, Gotlib J, Gupta V, et al. Management of cytopenias in patients with myelofibrosis treated with ruxolitinib and effect of dose modifications on efficacy outcomes. Onco Targets Ther. 2014;7:13\u201321. https:\/\/doi.org\/10.2147\/OTT.S53348.","journal-title":"Onco Targets Ther"},{"key":"1157_CR101","doi-asserted-by":"publisher","unstructured":"Harrison C, Andreasson B, Cambier N, et al. Long term safety of momelotinib in JAK inhibitor na\u00efve and previously JAK inhibitor treated intermediate\/high risk myelofibrosis patients. HemaSphere. 2020;4(S1):EP1113. https:\/\/doi.org\/10.1097\/HS9.0000000000000404.","DOI":"10.1097\/HS9.0000000000000404"},{"key":"1157_CR102","doi-asserted-by":"publisher","unstructured":"Kiladjian J-J, Platzbecker U, Mayer J, et al. Momelotinib\u2019s spleen, symptom and anemia efficacy is maintained in intermediate\/high-risk myelofibrosis patients with thrombocytopenia. Blood. 2020;136(S1):43\u201344. https:\/\/doi.org\/10.1182\/blood-2020-135880.","DOI":"10.1182\/blood-2020-135880"},{"key":"1157_CR103","doi-asserted-by":"crossref","first-page":"889","DOI":"10.2147\/TCRM.S258704","volume":"16","author":"S Bassiony","year":"2020","unstructured":"Bassiony S, Harrison CN, McLornan DP. Evaluating the safety, efficacy, and therapeutic potential of momelotinib in the treatment of intermediate\/high-risk myelofibrosis: Evidence to date. Ther Clin Risk Manag. 2020;16:889\u2013901.","journal-title":"Ther Clin Risk Manag"},{"key":"1157_CR104","doi-asserted-by":"publisher","unstructured":"Mesa R, Oh ST, Gerds AT, et al. Association of transfusion independence with improved overall survival in myelofibrosis patients receiving momelotinib. J. Clin. Oncol. 2021;39 (Suppl. 15); abstract 7046. https:\/\/doi.org\/10.1200\/JCO.2021.39.15_suppl.7046.","DOI":"10.1200\/JCO.2021.39.15_suppl.7046"},{"key":"1157_CR105","unstructured":"Gerds AT, Gotlib J, Bose P, et al. National Comprehensive Cancer Network (NCCN) Guidelines\u2212 Myeloproliferative Neoplasms. Version 2.2021. https:\/\/www.nccn.org\/guidelines\/category_1. Last accessed August 20, 2021."},{"key":"1157_CR106","doi-asserted-by":"publisher","unstructured":"Vannucchi AM, Barbui T, Cervantes F, et al. Philadelphia chromosome-negative chronic myeloproliferative neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(Suppl. 5):v85\u201399. https:\/\/doi.org\/10.1093\/annonc\/mdv203.","DOI":"10.1093\/annonc\/mdv203"},{"key":"1157_CR107","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/s41408-021-00526-z","volume":"11","author":"L Sureau","year":"2021","unstructured":"Sureau L, Orvain C, Ianotto J-C, et al. Efficacy and tolerability of Janus kinase inhibitors in myelofibrosis: a systematic review and network meta-analysis. Blood Cancer J. 2021;11:135.","journal-title":"Blood Cancer J"},{"key":"1157_CR108","doi-asserted-by":"publisher","unstructured":"Chifotides HT, Bose P, Masarova L, et al. SOHO State of the Art Updates and Next Questions: Novel therapies in development for myelofibrosis. Clin Lymph. Myeloma Leuk. 2022. https:\/\/doi.org\/10.1016\/j.clml.2021.10.002.","DOI":"10.1016\/j.clml.2021.10.002"}],"container-title":["Journal of Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-021-01157-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-021-01157-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-021-01157-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,28]],"date-time":"2022-03-28T08:15:05Z","timestamp":1648455305000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-021-01157-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,19]]},"references-count":108,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1157"],"URL":"https:\/\/doi.org\/10.1186\/s13045-021-01157-4","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,19]]},"assertion":[{"value":"12 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"P.B. reports honoraria from Incyte, Celgene (now BMS), CTI BioPharma, Kartos, Novartis, Sierra Oncology, and Blueprint Medicines; and research support from Incyte, Celgene (now BMS), CTI BioPharma, Kartos, Blueprint Medicines, Constellation, Astellas, Pfizer, NS Pharma, and Promedior. S.V. received research funding from Sierra Oncology, Incyte Corporation, Roche, NS Pharma, Celgene, Gilead, Promedior, CTI BioPharma Corporation, Genentech, Blueprint Medicines Corporation, Novartis, PharmaEssentia, AstraZeneca, Italfarmaco, Protagonist Therapeutics, Constellation Pharmaceuticals, Kartos Therapeutics, Prelude Therapeutics, AbbVie, Telios Pharmaceuticals, and Galecto. H.T.C. declares no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7"}}